Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supemtek immunogenicity and safety study in participants aged 9 to 49 years
2022-000577-11Phase 3Active
- Sponsor
- Sanofi
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Quadrivalent recombinant influenza vaccine in influenza (2 arms), sponsored by Sanofi. Primary endpoint: Individual hemagglutination inhibition titer at Day 29 after vaccination. Started Jun 2022; status: active.
02
Drugs
Quadrivalent recombinant influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2022-000577-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000577-11.